Scholarlink

<p>Individuals with atrial fibrillation (AF) are at increased risk of stroke, cognitive impairment and dementia. Observational studies suggest that anticoagulation may reduce the risk of cognitive decline in patients with AF and elevated thromboembolic risk, implicating subclinical cerebral emboli as a potential mechanistic link. Whether anticoagulation prevents cognitive deterioration in patients with AF at low risk of stroke remains uncertain. Here we conducted a multicenter, double-blind, placebo-controlled trial in which participants with AF and low thromboembolic risk (CHA<sub>2</sub>DS<sub>2</sub>-VASc scores of 0 or 1, excluding female sex) were randomized 1:1 to receive rivaroxaban 15 mg daily or placebo. The primary outcome was a composite of cognitive decline (≥2-point drop in Montreal Cognitive Assessment), stroke or transient ischemic attack with a motor deficit or aphasia. The trial was halted after meeting the predetermined futility criterion following a planned interim analysis, with 1,235 of the intended 1,424 participants (919 men; 316 women) enrolled. Over a median follow-up of 3.7 years, the primary outcome occurred in 256 (20.7%) participants, at an annual rate of 7.0% with rivaroxaban versus 6.4% with placebo, yielding a hazard ratio of 1.10 (95% confidence interval (0.86–1.40); <i>P</i> = 0.46). Conditional power analysis indicated a 1.2% probability of achieving a statistically significant treatment effect if the trial had been continued to its planned total of 410 events. Major bleeding occurred in two patients treated with rivaroxaban (0.09% per year) and five patients treated with placebo (0.21% per year). In conclusion, despite the high incidence of cognitive decline observed among patients with AF and low stroke risk, the BRAIN-AF trial, which tested a low dose of rivaroxaban to prevent stroke, transient ischemic attack and cognitive decline in patients with prior AF, was stopped early due to futility. ClinicalTrials.gov registration: <a href="https://clinicaltrials.gov/study/NCT02387229">NCT02387229</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月7日

查看全文
  • Léna Rivard,
  • Paul Khairy,
  • Mario Talajic,
  • Jean-Claude Tardif,
  • Jeffrey S. Healey,
  • Sandra E. Black,
  • Jason G. Andrade,
  • Thalia S. Field,
  • Isabelle Nault,
  • Louis Bherer,
  • Fadi Massoud,
  • Stanley Nattel,
  • Sylvain Lanthier,
  • Normand Racine,
  • Jean-François Roux,
  • Isabelle Greiss,
  • Laurent Macle,
  • Peter G. Guerra,
  • Rafik Tadros,
  • Hélène Mayrand,
  • Gilbert Gosselin,
  • David Conen,
  • Christian Bocti,
  • Céline Chayer,
  • Yan Deschaintre,
  • Roopinder K. Sandhu,
  • Jaimie Manlucu,
  • Yaariv Khaykin,
  • Atul Verma,
  • Blandine Mondésert,
  • Katia Dyrda,
  • Julia Cadrin-Tourigny,
  • Bernard Thibault,
  • Alexandre Raymond-Paquin,
  • Martin Aguilar,
  • Judith Brouillette,
  • André Roussin,
  • Alain Robillard,
  • Maxime Tremblay-Gravel,
  • Louis-Philippe David,
  • Mariève Cossette,
  • Ratika Parkash,
  • Marie-Claude Guertin,
  • Denis Roy,
  • A. Shekhar Pandey,
  • Francis Pichette,
  • Miguel Barrero,
  • Teresa Kus,
  • Ariane Lemieux,
  • Valérie Gaudreault,
  • Peiman Marzban,
  • Jorge Wong,
  • Peter Leong Sit,
  • David Laflamme,
  • Ronald Fowlis,
  • Kenneth Quadros,
  • Anmol Kapoor,
  • Umjeet S. Jolly,
  • Stephen Wilton,
  • Fabian Alejandro Azzari,
  • Paul Dorian,
  • François Deslongchamps,
  • Yves Pesant,
  • Saul Vizel,
  • TunZan Maung,
  • Michael Heffernan,
  • Pablo Nery,
  • Greg Curnew,
  • Stéphanie Bourgeois,
  • Vidal Essebag,
  • Simon Kouz,
  • Luc Cormier,
  • John Vyselaar,
  • Raja Chehayeb,
  • Clarence Khoo,
  • Anil Gupta,
  • Ricardo Bessoudo,
  • Rakesh Bhargava,
  • Franco Sandrin,
  • Gernot Schram,
  • François St-Maurice,
  • Winston Tsui,
  • William Liang

摘要

Individuals with atrial fibrillation (AF) are at increased risk of stroke, cognitive impairment and dementia. Observational studies suggest that anticoagulation may reduce the risk of cognitive decline in patients with AF and elevated thromboembolic risk, implicating subclinical cerebral emboli as a potential mechanistic link. Whether anticoagulation prevents cognitive deterioration in patients with AF at low risk of stroke remains uncertain. Here we conducted a multicenter, double-blind, placebo-controlled trial in which participants with AF and low thromboembolic risk (CHA2DS2-VASc scores of 0 or 1, excluding female sex) were randomized 1:1 to receive rivaroxaban 15 mg daily or placebo. The primary outcome was a composite of cognitive decline (≥2-point drop in Montreal Cognitive Assessment), stroke or transient ischemic attack with a motor deficit or aphasia. The trial was halted after meeting the predetermined futility criterion following a planned interim analysis, with 1,235 of the intended 1,424 participants (919 men; 316 women) enrolled. Over a median follow-up of 3.7 years, the primary outcome occurred in 256 (20.7%) participants, at an annual rate of 7.0% with rivaroxaban versus 6.4% with placebo, yielding a hazard ratio of 1.10 (95% confidence interval (0.86–1.40); P = 0.46). Conditional power analysis indicated a 1.2% probability of achieving a statistically significant treatment effect if the trial had been continued to its planned total of 410 events. Major bleeding occurred in two patients treated with rivaroxaban (0.09% per year) and five patients treated with placebo (0.21% per year). In conclusion, despite the high incidence of cognitive decline observed among patients with AF and low stroke risk, the BRAIN-AF trial, which tested a low dose of rivaroxaban to prevent stroke, transient ischemic attack and cognitive decline in patients with prior AF, was stopped early due to futility. ClinicalTrials.gov registration: NCT02387229.